Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Tyra Bioscience ( (TYRA) ) has shared an update.
Tyra Biosciences announced changes in its Board of Directors on January 28, 2025, with the resignation of Nina Kjellson and the appointment of Adele M. Gulfo. Gulfo brings extensive experience from her roles in major pharmaceutical companies like Sumitomo Pharma America, Mylan, and Pfizer. Her appointment is expected to strengthen Tyra Biosciences’ strategic direction, given her background in commercial and business development in the biopharmaceutical industry. With her appointment, Gulfo will also receive stock options and cash compensation under the company’s director compensation program.
More about Tyra Bioscience
YTD Price Performance: 6.65%
Average Trading Volume: 266,573
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $778.8M
See more insights into TYRA stock on TipRanks’ Stock Analysis page.